Cover Picture: Discovery of 5′′‐Chloro‐N‐[(5, 6‐dimethoxypyridin‐2‐yl)methyl]‐2, 2′:5′, 3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia (ChemMedChem 2/2014). Issue 2 (February 2014)
- Record Type:
- Journal Article
- Title:
- Cover Picture: Discovery of 5′′‐Chloro‐N‐[(5, 6‐dimethoxypyridin‐2‐yl)methyl]‐2, 2′:5′, 3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia (ChemMedChem 2/2014). Issue 2 (February 2014)
- Main Title:
- Cover Picture: Discovery of 5′′‐Chloro‐N‐[(5, 6‐dimethoxypyridin‐2‐yl)methyl]‐2, 2′:5′, 3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia (ChemMedChem 2/2014)
- Authors:
- Roecker, Anthony J.
Mercer, Swati P.
Schreier, John D.
Cox, Christopher D.
Fraley, Mark E.
Steen, Justin T.
Lemaire, Wei
Bruno, Joseph G.
Harrell, C. Meacham
Garson, Susan L.
Gotter, Anthony L.
Fox, Steven V.
Stevens, Joanne
Tannenbaum, Pamela L.
Prueksaritanont, Thomayant
Cabalu, Tamara D.
Cui, Donghui
Stellabott, Joyce
Hartman, George D.
Young, Steven D.
Winrow, Christopher J.
Renger, John J.
Coleman, Paul J. - Abstract:
- <abstract abstract-type="graphical" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>The front cover picture shows</bold> MK‐1064, a potent, orally bioavailable, selective orexin 2 receptor antagonist (2‐SORA) under evaluation as a potential treatment for insomnia. Orexin neuronal projections originating from the hypothalamus, shown in green, affect the activity of nuclei associated with arousal, vigilance state, and reward. Nuclei exhibiting preferential expression of orexin 1 receptor (OX1R), orexin 2 receptor (OX<sub>2</sub>R), and both OX<sub>1</sub>R and OX<sub>2</sub>R are shown in red, blue and violet, respectively. The lower left inlay depicts a homology model of OX<sub>2</sub>R bound by MK‐1064. The lower right inlay shows an orexin neuron secreting two peptide agonists, orexin‐A (OX‐A) and orexin‐B (OX‐B), and their binding to OX<sub>1</sub>R and OX<sub>2</sub>R. For more details regarding the discovery and development of MK‐1064, see the Full Paper by Anthony J. Roecker et al. on <ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">p. 311 ff.</ext-link> The homology modeling figure was provided by Dr. Kerim Babaoglu (Merck Chemistry Modeling and Informatics). Figure elements depicting the orexin neuron and receptor efferent pathways were taken from A. L. Gotter, A. L. Webber, P. J. Coleman, J. J. Renger, C. J. Winrow, <italic>Pharmacol. Rev.</italic> <bold>2012</bold>, <italic>64</italic>,<abstract abstract-type="graphical" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>The front cover picture shows</bold> MK‐1064, a potent, orally bioavailable, selective orexin 2 receptor antagonist (2‐SORA) under evaluation as a potential treatment for insomnia. Orexin neuronal projections originating from the hypothalamus, shown in green, affect the activity of nuclei associated with arousal, vigilance state, and reward. Nuclei exhibiting preferential expression of orexin 1 receptor (OX1R), orexin 2 receptor (OX<sub>2</sub>R), and both OX<sub>1</sub>R and OX<sub>2</sub>R are shown in red, blue and violet, respectively. The lower left inlay depicts a homology model of OX<sub>2</sub>R bound by MK‐1064. The lower right inlay shows an orexin neuron secreting two peptide agonists, orexin‐A (OX‐A) and orexin‐B (OX‐B), and their binding to OX<sub>1</sub>R and OX<sub>2</sub>R. For more details regarding the discovery and development of MK‐1064, see the Full Paper by Anthony J. Roecker et al. on <ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">p. 311 ff.</ext-link> The homology modeling figure was provided by Dr. Kerim Babaoglu (Merck Chemistry Modeling and Informatics). Figure elements depicting the orexin neuron and receptor efferent pathways were taken from A. L. Gotter, A. L. Webber, P. J. Coleman, J. J. Renger, C. J. Winrow, <italic>Pharmacol. Rev.</italic> <bold>2012</bold>, <italic>64</italic>, 389–420 and reproduced with permission from the American Society of Pharmacology and Experimental Therapeutics. The cover art was produced in conjunction with Sharon O'Brien (Merck Creative Services).<boxed-text content-type="graphic" position="anchor" orientation="portrait"><graphic position="anchor" mimetype="image" xlink:href="ark:/27927/pgg4smxcr2f" orientation="portrait" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink" /></boxed-text></p> </abstract> … (more)
- Is Part Of:
- ChemMedChem. Volume 9:Issue 2(2014:Feb.)
- Journal:
- ChemMedChem
- Issue:
- Volume 9:Issue 2(2014:Feb.)
- Issue Display:
- Volume 9, Issue 2 (2014)
- Year:
- 2014
- Volume:
- 9
- Issue:
- 2
- Issue Sort Value:
- 2014-0009-0002-0000
- Page Start:
- 241
- Page End:
- 241
- Publication Date:
- 2014-02
- Subjects:
- Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1860-7187 ↗
http://www3.interscience.wiley.com/cgi-bin/jhome/110485305 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cmdc.201490000 ↗
- Languages:
- English
- ISSNs:
- 1860-7179
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3172.254000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3785.xml